71
Sorafenib, a multitargeted kinase inhibitor used for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinomas, received FDA approval in 2005.
 Sorafenib: Treatment; a multitargeted kinase inhibitor: Treatment; Sorafenib: Treatment.Drug; unresectable hepatocellular carcinoma: Treatment.Disorder; advanced renal cell carcinomas: Treatment.Disorder
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: potential therapeutic event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Treatment.Time_elapsed, Subject.Disorder, Subject.Race, Treatment.Route, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 Sorafenib: Treatment; a multitargeted kinase inhibitor: Treatment; Sorafenib: Treatment.Drug; unresectable hepatocellular carcinoma: Treatment.Disorder; advanced renal cell carcinomas: Treatment.Disorder